A promising class of compounds for DNA transfection have been designed by conjugating various potyamines to bile-acid-based amphiphiles. Formulations containing these compounds were tested for their ability to facilitate the uptake of a 3-galactosidase reporter plasmid into COS-7 cells. Dioleoyl phosphatidyl ethanolamine (DOPE) formulations of some of the compounds were several times better than Lipofectin at promoting DNA uptake. The most active compounds contained the most hydrophilic bile acid components.The activity is clearly not related to affinity for DNA: the hydrophobic bile acid conjugates were found to form stable complexes with DNA at lower charge ratios than the hydrophilic conjugates. We suggest that the high activity of the best compounds is related to their facial amphiphilicity, which may confer an ability to destabilize membranes. The success of these unusual cationic transfection agents may inspire the design of even more effective gene delivery agents.Gene therapy is an exciting approach to the treatment of genetic defects, as well as diseases such as cancer and chronic viral infections (1-3). Unfortunately, the enthusiasm initially displayed for gene therapy has been tempered by the realization that there are no easy solutions to the problem of how to get genes into cells. The most efficient methods for transferring DNA across cell membranes involve the use of viral vectors (1, 4, 5); however, there are growing concerns about both the short-and long-term risks ofviral vectors. These concerns have prompted a search for other strategies for DNA delivery, and in the past few years, a variety of nonviral gene delivery systems have been investigated (6-9). Although some success in getting DNA into cells has been achieved, gene delivery with nonviral vectors remains an inefficient process. To make gene therapy a reality, more efficient DNA delivery systems are needed. In this paper, we report the design and preliminary evaluation of a promising class of DNA delivery agents. In designing these delivery agents, we started by considering the properties of existing nonviral delivery systems. Of all the nonviral DNA delivery systems that have been explored, cationic lipids have shown the most promise based on a combination of efficacy, stability, and toxicity. Lipofectin (Fig.

No abstract

Hydrophilic drugs are often poorly absorbed when administered orally. There has been considerable interest in the possibility of using absorption enhancers to promote absorption of polar molecules across membrane surfaces. The bile acids are one of the most widely investigated classes of absorption enhancers, but there is disagreement about what features of bile acid enhancers are responsible for their efficacy. We have designed a class of glycosylated bile acid derivatives to evaluate how increasing the hydrophilicity of the steroid nucleus affects the ability to transport polar molecules across membranes. Some of the glycosylated molecules are significantly more effective than taurocholate in promoting the intestinal absorption of a range of drugs, showing that hydrophobicity is not a critical parameter in transport efficacy, as previously suggested. Furthermore, the most effective glycosylated compound is also far less damaging to membranes than the best bile acid absorption promoters, presumably because it is more hydrophilic. The results reported here show that it is possible to decouple absorption-promoting activity from membrane damage, a finding that should spark interest in the design of new compounds to facilitate the delivery of polar drugs.

A novel, potent, and orally bioavailable inhibitor of hepatitis C RNA replication targeting NS4B, compound 4t (PTC725), has been identified through chemical optimization of the 6-(indol-2-yl)pyridine-3-sulfonamide 2 to improve DMPK and safety properties. The focus of the SAR investigations has been to identify the optimal combination of substituents at the indole N-1, C-5, and C-6 positions and the sulfonamide group to limit the potential for in vivo oxidative metabolism and to achieve an acceptable pharmacokinetic profile. Compound 4t has excellent potency against the HCV 1b replicon, with an EC50 = 2 nM and a selectivity index of >5000 with respect to cellular GAPDH. Compound 4t has an overall favorable pharmacokinetic profile with oral bioavailability values of 62%, 78%, and 18% in rats, dogs, and monkeys, respectively, as well as favorable tissue distribution properties with a liver to plasma exposure ratio of 25 in rats.

No abstract